Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade.

Journal for immunotherapy of cancer - 1 Dec 2022

Zheng Ming

Abstract excerpt

As we look forward to the bright future of immune checkpoint blockade (ICB) therapy, there is still lacking a pharmacokinetic marker to understand the inter-individual differences in ICB response. ICB therapy is based on IgG antibodies that share the same homeostatic pathway with serum albumin. Therefore, serum albumin level could reflect IgG catabolic rate that directly impacts the clearance of therapeutic IgG...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Reproducibility of Results

Share to Serum Albumin

Share to Treatment Outcome

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 36600664
DOI: 10.1136/jitc-2022-005670
PMCID: PMC9772729

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade.PMID 36600664Read ↗

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.Semantic proximity Read ↗

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanomaSemantic proximity Read ↗

Half-life extension using serum albumin-binding DARPin® domainsSemantic proximity Read ↗

Quantitative Prediction of Human Pharmacokinetics for Fc-Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection.Semantic proximity Read ↗

Prognostic Value of Baseline HbA1c in Advanced Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Retrospective Cohort StudySemantic proximity Read ↗

Development and validation of a semi-automated hybrid immunocapture liquid chromatography-mass spectrometry method to quantify LALA-mutated biotherapeutics in mouse plasma.Semantic proximity Read ↗

Activity-based urinary biomarkers of response and resistance to checkpoint blockade immunotherapySemantic proximity Read ↗

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myelomaSemantic proximity Read ↗

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitorsSemantic proximity Read ↗

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunctionSemantic proximity Read ↗

Using Virtual Patients to Evaluate Dosing Strategies for Bispecifics with a Bell-Shaped Efficacy CurveSemantic proximity Read ↗

Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.